Skip to main content


Fig. 7 | Clinical and Translational Medicine

Fig. 7

From: The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats

Fig. 7

The pharmacodynamics assay in the hPCSK9 transgenic rat model. The horizontal axis represents the timeline (days post the first treatment). The vertical axis represents the CHOL (A), LDL-c (B) levels (mmol/L) and their percent change (%) was given on the right (←). ‘SD’ was the normal Sprague Dawley rat. ‘Tg+’ represents the hPCSK9 transgenic SD rat; ‘high fat’ refers to the feeding of the high fat diet to the rat. ‘Evolo’ represents the rat treated with the evolocumab. ‘PBS’ represents the rat injected with the PBS buffer. ‘↓’ represents the two treatments on day 0 and day 7. ‘×’ represents the sacrifice of the animals on day 20. P < 0.05 was considered as statistically significant, compared with the PBS group (*P < 0.05, **P < 0.01; ns: not significant)

Back to article page